GCP
INBX icon

GSA Capital Partners’s Inhibrx INBX Stock Holding History

GSA Capital Partners’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-33,747
Closed -$520K – 1844
2024
Q4 		$520K Sell
33,747
-7,778
-19% -$118K 0.04% 857
2024
Q3 		$650K Buy
41,525
+18,293
+79% +$257K 0.05% 740
2024
Q2 		$329K Buy
+23,232
New +$363K 0.02% 1216

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
Slotnik Capital Dallas, Texas $342M AUM 105.92% 1-Year Est. Return

GSA Capital Partners's INBX Position: Q1 2025 in Review

GSA Capital Partners sold out of Inhibrx (INBX) in Q1 2025, closing a stake of 33,747 shares — an estimated $520K sold.

GSA Capital Partners first reported a position in INBX in Q2 2024 and held it in 3 quarters. The position peaked at $650K in Q3 2024. 92 funds tracked by Wall St. Rank hold INBX as of Q1 2025.

  • GSA Capital Partners reported no remaining Inhibrx position as of Q1 2025 after selling out during the quarter.
  • GSA Capital Partners sold 33,747 Inhibrx shares in Q1 2025, an estimated $520K.
  • GSA Capital Partners first reported a position in Inhibrx in Q2 2024 and held it in 3 quarters.
  • GSA Capital Partners's Inhibrx position peaked at $650K in Q3 2024.
  • 92 funds tracked by Wall St. Rank held Inhibrx as of Q1 2025.

Based on GSA Capital Partners's 13F filing for Q1 2025, filed 8 May 2025.